People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Montara Therapeutics, Inc. | — | Biotechnology | Series B | $28.0M | $107.6M | 2024 |
| Mitokinin, Inc. | — | Biotechnology | Series A | $9.5M | $180.8M | 2017 |
Nicholas Hertz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicholas Hertz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas Crawford | 1 | 8 |
| TROY WILSON | 1 | 7 |
| Peter Parker | 1 | 6 |
| Doug Crawford | 1 | 3 |
| Zachary Hill | 1 | 2 |
| Johannes Fruehauf | 1 | 2 |
| Daniel De Roulet, Jr. | 1 | 1 |
| Max Lebovitz | 1 | 1 |
| Seth Stratton | 1 | 1 |
| Rishi Rakhit | 1 | 1 |
| Randall Chin | 1 | 1 |
| Dirk Langdorf | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.